The Cleveland Clinic’s new Center for Global and Emerging Pathogens Research now takes on the challenge of ensuring the world is more ready for the next epidemic or pandemic. This important Cleveland Clinic research center not only investigates emerging pathogens, such as Zika and COVID-19, but also targets treatments and vaccines to protect society from emerging public health threats. Led by director Jae Jung, the center focuses on the investigation into viruses, immunology, personal medicine, genetics, population health, and more. It’s a place where multiple disciplines converge and collaborate to discover and develop novel drugs, vaccines, and diagnostic tests.
The pathogens research center collaborates with drug developers at Lerner Research Institute’s Center for Therapeutics Discovery to translate data from lab to life-saving therapies. TrialSite has emphasized the critical importance of the social determinants of health for health system transformation: that a sizeable amount of health care issues are actually social issues. Cleveland Clinic understands this and its Populations Health Research Center will offer social determinant of health data impacting the risk of infection to inform research moving forward.
Note Jae Jung was just appointed as chair of Cleveland Clinic Lerner Research Institute’s Department of Cancer Biology as well as director of the new center.